Report cover image

Adrenomyeloneuropathy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Publisher BIS Research
Published Oct 22, 2025
SKU # BIS20490109

Description

Global Adrenomyeloneuropathy Market: Industry Overview

The global adrenomyeloneuropathy market is expected to grow steadily, reaching a significant market size by 2035. Key drivers of this growth include the orphan disease status, which accelerates regulatory approvals and market exclusivity, and ongoing clinical trials coupled with increased R&D investments, which are expanding the treatment pipeline and fuelling market expansion.

Despite these drivers, the market faces challenges such as the high cost of gene therapies and advanced drug delivery systems, which may limit affordability and accessibility. Additionally, as a rare disorder, adrenomyeloneuropathy has a smaller patient pool, impacting its economic viability and market size.

Demand – Drivers and Limitations

The demand drivers for the global adrenomyeloneuropathy market are:

Orphan disease status helps expedite regulatory approvals and market exclusivity, incentivizing drug development
Ongoing clinical trials and higher R&D investments are broadening the treatment pipeline and fuelling market growth

Limitations:

Expensive gene therapies and advanced drug delivery systems may limit affordability and accessibility

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report offers a comprehensive overview of the current treatment landscape in adrenomyeloneuropathy, highlighting emerging trends such as gene therapies and personalized medicine. Organizations can leverage this information to identify opportunities for product innovation, focusing on unmet needs in treatment efficacy, side effects, and early intervention strategies.

Competitive Strategy: To maintain a competitive edge in the global adrenomyeloneuropathy market, companies should focus on enhancing the safety and affordability of their therapies, exploring strategic partnerships for R&D, and investing in gene therapy development. Collaborating with research institutions and pursuing regulatory incentives for rare disease treatments could further strengthen market position.

Key Market Players and Competition Synopsis

The companies profiled in this report are based on extensive research and insights from primary experts, evaluating company coverage, product portfolios, and market penetration. The leading players in the global adrenomyeloneuropathy market are pharmaceutical companies making significant advancements in therapies for adrenomyeloneuropathy. These companies are at the forefront of improving patient outcomes and addressing the growing demand for effective treatments for rare neurodegenerative disorders.

Some of the prominent pharmaceutical companies established in the global adrenomyeloneuropathy market include:

Bluebird bio, Inc.
Minoryx Therapeutics
MedDay Pharmaceuticals
Orpheris, Inc.

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria
1. Global Adrenomyeloneuropathy Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis of Adrenomyeloneuropathy
1.2.1 U.S.
1.2.2 EU5
1.2.3 Rest-of-the-World
1.3 Market Trends
1.4 Clinical Trial Analysis
1.4.1 By Phase
1.5 Regulatory Landscape Analysis
1.5.1 Legal Requirement and Framework in U.S.
1.5.2 Legal Requirement and Framework in E.U.
1.5.3 Legal Requirement and Framework in Asia-Pacific
1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Adrenomyeloneuropathy Market, by Region, $Million, 2024-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Adrenomyeloneuropathy Market (by Country)
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Adrenomyeloneuropathy Market (by Country)
2.2.3.1.1 Germany
2.2.3.1.2 France
2.2.3.1.3 Italy
2.2.3.1.4 U.K.
2.2.3.1.5 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Adrenomyeloneuropathy Market (by Country)
2.3.3.1.1 Japan
2.3.3.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Sizing and Forecast
3. Global Adrenomyeloneuropathy Market: Competitive Benchmarking and Company Profiles
3.1 Competitive Benchmarking
3.2 Competitive Landscape
3.2.1 Key Strategies and Developments by Company
3.2.1.1 Funding Activities
3.2.1.2 Mergers and Acquisitions
3.2.1.3 Regulatory Approvals
3.2.1.4 Partnerships, Collaborations and Business Expansions
3.2.2 Key Developments Analysis
3.3 Company Profiles
3.3.1 Bluebird bio, Inc.
3.3.1.1 Company Overview
3.3.1.2 Product Portfolio
3.3.1.3 Target Customers/End Users
3.3.1.4 Key Personnels
3.3.1.5 Analyst View
3.3.2 Minoryx Therapeutics
3.3.2.1 Company Overview
3.3.2.2 Product Portfolio
3.3.2.3 Target Customers / End Users
3.3.2.4 Key Personnels
3.3.2.5 Analyst View
3.3.3 MedDay Pharmaceuticals
3.3.3.1 Company Overview
3.3.3.2 Product Portfolio
3.3.3.3 Target Customers / End Users
3.3.3.4 Key Personnels
3.3.3.5 Analyst View
3.3.4 Magenta Therapeutics, Inc.
3.3.4.1 Company Overview
3.3.4.2 Product Portfolio
3.3.4.3 Target Customers / End Users
3.3.4.4 Key Personnels
3.3.4.5 Analyst View
3.3.5 Orpheris, Inc.
3.3.5.1 Company Overview
3.3.5.2 Product Portfolio
3.3.5.3 Target Customers / End Users
3.3.5.4 Key Personnels
3.3.5.5 Analyst View
4. Research Methodology
List of Figures
Figure: Global Adrenomyeloneuropathy Market, 2024 and 2035
Figure: Global Adrenomyeloneuropathy Market - Coverage
Figure: Global Adrenomyeloneuropathy Market, Key Trends, Impact Analysis
Figure: Global Adrenomyeloneuropathy Market, Competitive Landscape
Figure: North America Adrenomyeloneuropathy Market, $Million, 2024-2035
Figure: Europe Adrenomyeloneuropathy Market, $Million, 2024-2035
Figure: Asia-Pacific Adrenomyeloneuropathy Market, $Million, 2024-2035
List of Tables
Table: Market Snapshot
Table: Global Adrenomyeloneuropathy Market, Impact Analysis
Table: Global Adrenomyeloneuropathy Market, Regulatory Landscape
Table: Global Adrenomyeloneuropathy Market, (by Region), $Million, 2024-2035

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us